Progress in therapy development for amyotrophic lateral sclerosis - Wikidata - wikimedia - TriplyDB

Progress in therapy development for amyotrophic lateral sclerosis

Progress in therapy development for amyotrophic lateral sclerosis

http://www.wikidata.org/entity/Q34640800

about

Protein kinase CK-1 inhibitors as new potential drugs for amyotrophic lateral sclerosis.A common gene expression signature in Huntington's disease patient brain regions.Empowerment of patients in online discussions about medicine use.Suicidal Behavior and Neurological Illnesses.

P2860

Q30574827-A1D1EC2E-999A-44D5-84B4-1FD371E9E103 Q34446889-AD4BF07C-5F6C-4FB5-84A8-A3D6A9E64B6B Q35425307-5A7C8E2E-C83B-42F8-B838-850A7285182B Q37541970-79ED0BD1-D52D-44E4-A94B-F9F7D94B6747

P2860

Progress in therapy development for amyotrophic lateral sclerosis

http://www.wikidata.org/entity/Q34640800

description

2012 nî lūn-bûn

@nan

2012 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Progress in therapy development for amyotrophic lateral sclerosis

@ast

Progress in therapy development for amyotrophic lateral sclerosis

@en

Progress in therapy development for amyotrophic lateral sclerosis

@nl

type

label

Progress in therapy development for amyotrophic lateral sclerosis

@ast

Progress in therapy development for amyotrophic lateral sclerosis

@en

Progress in therapy development for amyotrophic lateral sclerosis

@nl

prefLabel

Progress in therapy development for amyotrophic lateral sclerosis

@ast

Progress in therapy development for amyotrophic lateral sclerosis

@en

Progress in therapy development for amyotrophic lateral sclerosis

@nl

P1433

Q34640800-104A2CA2-4C00-455A-9999-78B9C5D292C0

P1476

Q34640800-750F8692-3B4C-4E87-BFF2-E10689178C05

P2093

Q34640800-30E3A7E2-4BF9-4E75-8A2E-D7B3806C18EA

Q34640800-5860F59C-6D33-486C-811C-E3EB2D0F7C31

Q34640800-604E48E1-7A24-4338-A824-0E209E632C11

Q34640800-6C4532B6-731E-4E2A-A74B-8BFDCADB8BE6

Q34640800-B380AC74-4A7F-4CE3-A0DE-D56D830DA4ED

P2860

Q34640800-03D9D6D2-E7BC-4775-A5C7-3F060B4E2D0C

Q34640800-07F6EF4E-397A-4186-A9C6-A86C92DAA8DF

Q34640800-09DFE073-F793-4976-88FB-5A7088DDA8DD

Q34640800-0AAA3E62-335F-4466-9840-CCD3E7720B97

Q34640800-0ED5F5F6-A81C-4B87-85E5-02D6ABB15481

Q34640800-137FC7D6-04CD-4C1E-955C-F5EC9DC22484

Q34640800-145F7F3E-7B5B-4D52-BB1A-428A424609B7

Q34640800-1A31E229-228E-47FA-9084-41A12949B3C7

Q34640800-1E9D0271-4260-4FCE-B87E-041AA70F41E4

Q34640800-254A478E-613B-4125-AC74-4A654D869EF6

P304

Q34640800-37151991-F1A0-4D89-9D0B-7682BE121ADB

P31

Q34640800-3CEB64D1-4701-4932-97C9-60CFADA7333A

P356

Q34640800-2B93F93C-8263-460E-BD95-2ABF75440331

P478

Q34640800-28B41E30-7524-4070-8B6F-8DB0B6C845E3

P577

Q34640800-4545A3E9-0C51-4E14-A9BE-D8B597CA8BAD

P5875

Q34640800-80B31BA4-A0AE-472D-9C2C-E4F6E7CC4054

P698

Q34640800-30BA124A-DA74-4968-B9F8-AE6207F4BD45

P921

Q34640800-FBE26E45-4516-414C-B11C-9EB24B6CCC26

P932

Q34640800-FA0B9FB0-0974-46B1-B9C5-BF993DABAF83

P356

P1433

Neurology Research International

P1476

Progress in therapy development for amyotrophic lateral sclerosis

@en

P2093

Alexandar Christov

http://www.w3.org/2001/XMLSchema#string

Kalina Venkova-Hristova

http://www.w3.org/2001/XMLSchema#string

Kenneth Hensley

http://www.w3.org/2001/XMLSchema#string

Peter Kobalka

http://www.w3.org/2001/XMLSchema#string

Zarine Kamaluddin

http://www.w3.org/2001/XMLSchema#string

P2860

Riluzole for amyotrophic lateral sclerosis (ALS)/motor neuron disease (MND)

Chromosome 9p21 in amyotrophic lateral sclerosis in Finland: a genome-wide association study

Primary glia expressing the G93A-SOD1 mutation present a neuroinflammatory phenotype and provide a cellular system for studies of glial inflammation

The expression of the chemorepellent Semaphorin 3A is selectively induced in terminal Schwann cells of a subset of neuromuscular synapses that display limited anatomical plasticity and enhanced vulnerability in motor neuron disease

Design, power, and interpretation of studies in the standard murine model of ALS

Nordihydroguaiaretic acid increases glutamate uptake in vitro and in vivo: therapeutic implications for amyotrophic lateral sclerosis

Lenalidomide (Revlimid) administration at symptom onset is neuroprotective in a mouse model of amyotrophic lateral sclerosis.

Collapsin response mediator protein 4a (CRMP4a) is upregulated in motoneurons of mutant SOD1 mice and can trigger motoneuron axonal degeneration and cell death.

Proteomic identification of binding partners for the brain metabolite lanthionine ketimine (LK) and documentation of LK effects on microglia and motoneuron cell cultures.

Larrea tridentata (Creosote bush), an abundant plant of Mexican and US-American deserts and its metabolite nordihydroguaiaretic acid.

P304

187234

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1155/2012/187234

http://www.w3.org/2001/XMLSchema#string

P478

2012

http://www.w3.org/2001/XMLSchema#string

P577

2012-07-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

230566270

http://www.w3.org/2001/XMLSchema#string

P698

22830014

http://www.w3.org/2001/XMLSchema#string

P921

amyotrophic lateral sclerosis

P932

3399448

http://www.w3.org/2001/XMLSchema#string